Women with sickle cell disease have an increased risk of adverse pregnancy outcomes for the mother and the fetus. Voxelotor should only be used during pregnancy if the benefit of the drug outweighs the potential risk.

September 2024: The sickle cell treatment voxelotor (Oxbryta) has been withdrawn from all markets by the manufacturer Pfizer after a “higher than anticipated” number of deaths were reported and clinical evidence showed that the drug’s benefits no longer outweighed the risks.